Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Avexa Rises on Licensing Pact for Potential HIV Drugs

July 14 (Bloomberg) -- Avexa Ltd. climbed in Sydney trading after the company said it entered into a licensing agreement in China to develop a potential class of treatments for HIV.

Avexa gained 12 percent to close at 3.7 Australian cents. Australia’s S&P/ASX 200 Index rose 1.9 percent.

The Melbourne-based drug developer will receive 50 percent of revenue from the drugs in China under the agreement with Shanghai Institute of Organic Chemistry, which will bear development costs in the country, Avexa said in a statement today. Avexa retains all development and marketing rights outside the China region, the company said.

To contact the reporter on this story: Lena Lee in Singapore at

To contact the editor responsible for this story: Lena Lee at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.